- Poster discussion presentation
- Open Access
PD38 - Clinical features and natural history of cold contact urticaria in children
© Pananaki et al; licensee BioMed Central Ltd. 2014
- Published: 28 February 2014
- Personal History
- Cold Exposure
- Skin Area
Cold contact urticaria (CCU) or Acquired cold urticaria is a common subtype of physical urticaria characterized by itchy wheals and/or angioedema after cold exposure. However, extensive cold contact of large skin areas may lead to systemic reactions.The prevalence and course of CCU is not well defined.
To present epidemiological and clinical data of children with CCU, natural progression and to examine this progression according to the cold stimulation test (CST).
Data were collected from 32 children with cold urticaria≤18 years old who have been evaluated at the Allergy Unit of PandA Kyriakou Children’s Hospital. Demographic data, personal history, laboratory testing, cold stimulation testing (CST), atopy assessment, medication and disease severity were recorded. Telephone interviews of patients and/or their parents, or annual consultations were performed in order to obtain follow up data.
We excluded 2 patients because secondary causes were found. The most common trigger was swimming in the sea. History for atopy was present only in 37% of patients.The mean age of onset was 9.2±3.4 years old. Roc analysis for CST with respect to the presence of prior anaphylaxia revealed that the optimal cut off for the test was the 3 minutes. This cut off, presented a sensitivity of 90% and a specificity of 82.4%. The AUC was 0.826, 95%CI:[0.636-1].The median duration of surveillance was 70,4 months. During this time interval 17% showed persistent or even worsening symptomatology, 27% reported improvement, while 30% overcame their symptoms; we had no current data for 27%. There was a trend for an association of the CST with disease outcome; however, the numbers were small for a conclusion.
CCU in children is a chronic persistent disorder. The CST is a good predictor for anaphylaxis. It is currently difficult to predict when and in which patient the symptoms will resolve.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.